Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rooij, L van
SUPERNEXT, NCT04225312: Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis	Enrolling by invitation	4	300	Europe	Personalized extended interval dosing of natalizumab, EID, Standard interval dosing, SID	Amsterdam UMC, location VUmc, Stichting MS Research, Innovatiefonds Zorgverzekeraars, Stichting Treatmeds	Relapsing Remitting Multiple Sclerosis	03/25	03/25